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Abstract
In recent studies, non-coding protein RNAs have been identified as mi-
croRNA that can be used as biomarkers for early diagnosis and treatment
of cancer, that decrease mortality in cancer. A microRNA may target hun-
dreds or thousands of genes and a gene may regulate several microRNAs,
so determining which microRNA is associated with which cancer is a big
challenge. Many computational methods have been performed to detect
micoRNAs association with cancer, but more effort is needed with higher
accuracy. Increasing research has shown that relationship between microR-
NAs and TFs play a significant role in the diagnosis of cancer. Therefore, we
developed a new computational framework (CAMIRADA) to identify cancer-
related microRNAs based on the relationship between microRNAs and dis-
ease genes (DG) in the protein network, the functional relationships between
microRNAs and Transcription Factors (TF) on the co-expression network,
and the relationship between microRNAs and the Differential Expression
Gene (DEG) on co-expression network. The CAMIRADA was applied to
assess breast cancer data from two HMDD and miR2Disease databases. In
this study, the AUC for the 65 microRNAs of the top of the list was 0.95,
which was more accurate than the similar methods used to detect microRNAs
associated with the cancer artery.
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1. Introduction
According to a study,breast cancer is one of the most common causes of
women’s deaths in cancer [1]. The molecular traits of the primary tumors
play an important role in timely diagnosis and treatment of the next stages of
breast cancer. Therefore, we need methods that can detect cancer at an early
stage in order to help clinicians and patients to be treated with biological
markers [1]. In recent years, many studies have been conducted to clarify the
mechanisms that make cancer progress and develop.
Although many genes that cause cancer and stop it are known by re-
searchers, it is still necessary to identify cancer pathways. Therefore, one
of the most important biological targets of cancer is the detection of genes
related to cancers [2, 3].
MicroRNAs are short non-coding RNAs with an approximate length of 22
nucleotides that are involved in post-transcriptional regulation and that are
major regulators of gene expression [4].In 2002, the first link between cancer
and microRNAs was identified [5]. MicroRNAs target about 60% of human
genes that be involved in a wide range of biological processes and disease
including cell division, proliferation, differentiation, and apoptosis [6]. More
than 50% of human microRNAs are located in cancer-associated genomic
regions. MicroRNAs could play roles as oncogenes or tumor suppressor genes.
Dysregulation of microRNAs expression has been shown to have impacts on
human diseases [6].
However, identifying the related microRNAs with existing experimental
tests may be difficult and time consuming. In addition, many researchers are
also faced with limited knowledge about microRNAs. Therefore, a number
of computational approaches have been recently developed to identify mi-
croRNAs associated with the disease. Statistical methods, machine learning,
and network-based methods are some of the methods proposed to predict
cancer-related microRNAs.
Zhao et al. developed a framework for obtaining the relationship between
cancer and microRNAs through their target gene expression profiles without
requiring neither microRNA expression data or the matched gene and mi-
croRNAs expression data. For each microRNA, target genes that are likely
to be related to cancer are determined, and subsequently identified adverse
pathways associated with cancer. Then, microRNAs are ranked according
to these pathways, because high-ranking microRNAs are more likely to be
linked to cancer [7].
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Xue et al. used the Gaussian mixture models, they identified patterns of
gene expression for healthy and patient samples, and then, with Fisher’s exact
test, deduced the regulator relationship between TF and genes. A minimum
description length for the pruning of the network, using the (MDL) principle,
the relationships between TFs and microRNAs have been achieved [8].
Tseng et al. provided a method to identify active oncomirs and their po-
tential functions in gastric cancer progression. The microRNA and mRNA’s
expression profiles with the human protein interaction network (PIN) are in-
tegrated to show microRNAs-regulated PIN in specific biological conditions.
The microRNAs’ potential functions were identified by functional enrichment
analysis and the activities of microRNAs-regulated PINs were evaluated by
the co-expression of protein-protein interactions (PPIs) [9].
Le constructed microRNAs functional similarity networks based on shared
targets of microRNAs, and then it integrated them with a microRNA func-
tional synergistic network. After analyzing topological properties of these
networks, it introduced five network-based ranking methods (RWR, PRINCE
(Prioritization and Complex Elucidation), which was proposed for disease
gene prediction; PageRank with Priors (PRP) and K-Step Markov (KSM),
which were used for studying web networks; and a neighborhood-based algo-
rithm.) in prioritizing candidate microRNAs to predict novel disease-related
microRNAs based on the constructed microRNAs functional similarity net-
works [6].
In this study, we presented CAMIRADA framework for the identification
of microRNAs cancer associations by taking advantage of the useful links
between microRNAs targets and disease genes in protein-protein networks
(PPIs), the functional connections between microRNAs targets and Tran-
scription Factors(TF) in co-expression network and the functional relation-
ships between microRNAs targets and Differentially Expressed Gene(DEG)
in co-expression network.
2. Methods
2.1. Data Sets
We firstly collected the microRNAs target genes predicted with different
tools, including PicTar [10], miRanda (version 3.0) [11], TargetScan (release
6.2) [12], miRBase (version 16) [13] and mirTarbase [14]. Specifically, for a
microRNA, we consider target genes to be obtained at least by three tools.
Note that some microRNAs are not considered if, after filtering, its target
3
genes are less than three. In total, we obtained 42832 targeting pairs that
involved 825 microRNAs and 8334 target genes.
The disease-gene association data were obtained from DisGeNET [15]
and The Candidate Cancer Gene Database (CCGD) [16], which involved 375
genes related to breast cancer. The Transcription factors(TF) were retrieved
from ChIPBase [17], that included 13890 genes. The names of all these genes
mapped to Entrez gene id.
2.2. Human Protein-Protein Interaction (PPI) Data And Co-Expression Net-
work
PPI data for humans are derived from the Human Protein Reference
Database (HPRD Release 9), which contains human-protein annotations
based on empirical evidence from published reports [18]. We changed the
name of the gene to the Entrez gene id, and then we obtained the maximum
components of the entire network, which contains 9028 genes and 35865 in-
teractions. It is noteworthy that PPI data in HPRD are the most common
protein isoforms, mainly due to lack of experimental data [12].
We downloaded GSE31192 [19] data from the GEO [20] database to build
a co-expression network and obtain DEGs. The RNA extracted from breast
tissue with microarrays Affymetrix Human Genome U133 Plus 2.0 has been
investigated. These gene expression data are pre-processed with the Robust
Multichip Average algorithm(RMA).
Then we find out the Differentially Expressed Genes (DEGs) between
normal and abnormal samples with samr package in R. We selected genes,
which their p − value were under 0.05 and their nfold was 0.1 . The co-
expression network was constructed using the WGCNA [21] package in R
software. To choose an appropriate cutoff to include a percentage of the high-
est correlations, the approximate scale-free topology criterion was applied.
For determining the optimal parameter, the function pickSoftThresholdthe
in WGCNA package was used. After selecting the best threshold (0.85),
adjacency network for co-expression network was calculated.
The co-expression network included 21179 genes, so for sampling, we
considered DEGs and all targets of microRNAs as seed, we mapped them
onto the co-expression network, and after that, we applied RWR (Random
Walk With Restart) algorithm for ranking the genes of network [18]. Then we
selected top 10000 genes and made the network base on their relationships.
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2.3. CAMIRADA algorithm
2.3.1. Disease Genes-microRNAs
We mapped targets of a microRNA and disease genes onto PPI network.
After that, we considered disease genes as seeds and applied RWR [18] to
rank genes of PPI network. Then by using gene set enrichment analysis
(GSEA) we derived the ranked gene list, we used ES1 (enrichment score)
using the following formula [18].
ES1 = max
1≤i≤n


∑
gj∈TG,
j≤i
√
N − n1
n1
−
∑
gj /∈TG,
j≤i
√
N − n1
n1

 (1)
Where N is the number of all genes in PPI network and n1 is the num-
ber of target genes of one microRNA that we showed with TG. For each
microRNA we calculate ES1. We computed a statistical sum from the be-
ginning of the ranked list of PPI’s genes. In this way, by moving down the
list if the gene was in TG, we added to statistical sum, and if that gene did
not exist in the TG, we reduced from statistical sum. The RWR algorithm
with each microRNA’s target genes as seeds was applied to compute ES2 for
the same pairing of microRNAs disease referred to above [18].
ES2 = max
1≤i≤n


∑
gj∈DG,
j≤i
√
N − n1
n1
−
∑
gj /∈DG,
j≤i
√
N − n1
n1

 (2)
Which n2 is the number of disease genes. For all pairs of microRNAs and
disease genes we did the above procedures. For computing ES1 we considered
disease genes as seed for RWR algorithm and we considered targets of one
microRNA as seed for RWR to compute ES2. Then we calculated ES for
each pair of microRNAs-disease by using the following formula [18]
ES = β ES1 + (1− β) ES2 (3)
2.3.2. DEGs-microRNAs
We mapped targets of each microRNA and DEG onto co-expression net-
work. For all pairs of microRNAs and DEGs we calculated ES. For computing
ES1 we considered DEGs as seed for RWR algorithm and we considered tar-
gets of one microRNA as seed for RWR to compute ES2. Then we calculated
ES for each pair of microRNAs-DEG Where N is the number of all genes
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Figure 1: An overview of our framework to predict new diseases associated with
microRNAs.
in co-expression network and n1 is the number of target genes of one mi-
croRNA. For each microRNA we calculate ES1 1. Which n2 in the ES2 2 is
the number of DEGs.
2.3.3. TFs-microRNAs
We did all above producers on TF and targets of microRNAs. First
in order, we mapped targets of all microRNAs and TFs onto co-expression
network and for each microRNA we separately saved it’s targets in a list. For
all pairs of microRNAs and TFs we calculated ES 3. For computing ES1 we
considered TFs as seed for RWR algorithm and we considered targets of one
microRNA as seed for RWR to compute ES2. Then we calculated ES for each
pair of microRNAs-TFs Where N is the number of all genes in co-expression
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network and n1 is the number of target genes of one microRNA. For each
microRNA we calculate ES1 1. Which n2 in the ES2 2 is the number of TFs.
A review of our frame work are showed in Figure 1.
2.4. Random Network And P-value
To measure the importance of the relationship between microRNAs and
disease, we used the p-value. To calculate the p-value, we first created 1000
random networks of the PPI network and 1000 random networks of the co-
expression network. Random networks were made in such a way that the
number of input and output edges from each node with the number of input
and output edges from the same node in the primary network are equal
[18]. Of course, it should be noted that both the PPI network and the co-
expression network are non-directional networks in this study. The p-value
is calculated based on [18].
3. Results And Performance
To evaluate the performance of our algorithm to identify microRNAs-
disease associations, we plotted the receiver operating characteristic (ROC)
curves and computed the area under the curve (AUC).
To compute the AUC, we first need to calculate the sensitivity and speci-
ficity based on the following formulas, and the sensitivity is defined as the
correct detection rate of the positive group on the y axis and the specificity,
or the wrong detection rate of the negative category on the x axis. A ROC
curve shows a relative compromise between profits and costs [6].
1− specificity =
FP
TN + FP
(4)
1− Sensitivity =
TP
FN + TP
(5)
For computing of these we needed to define the set of TP TN FP and
FN . At first we should define positive set and negative set. For positive
set we considered the known cancer related microRNAs were obtained from
miR2Disease [22] and HMDD [23] databases.
Nowadays, it is very difficult or impossible to collect data for non-cancerous
microRNA [24]. For a negative data set, we chose microRNAs that exhibited
the lowest fold change values as negative controls by analyzing the corre-
sponding expression profile of the breast cancer. We also used the same
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Figure 2: Computing AUC for each three list of p-value for DEG-microRNAs,
Disease-microRNAs and TF-microRNAs. And we calculated AUC for CAMI-
RADA.
number of negative controls as positive ones. We downloaded microRNAs
expression profile GSE45666 [24] from GEO.
We computed three lists of p-value for microRNAs according to our
method. We arranged lists of p-value by descending order and we calculated
AUC for each list to identify the importance of each factor (TF, disease and
DEG) for determining which microRNA is associated with breast cancer.
As the Figure 2 shows, the lowest AUC is for disease-microRNAs and
the maximum AUC is for CAMIRADA approach. So, this shows that DEGs
and TFs influence on identification of which microRNAs are related to breast
cancers. For using the influence of TFs and DEGs on identification of mi-
croRNAs, we combined p-vlues with some tests in R.
The tests included Wilkinsonp, sumlog, sumz, logitp, meanp and sump
from metap [25] package in R. Then we scored microRNAs according to our
model. For each p-value as threshold, we computed TP , TN , FP and FN
by using the following definition:
• TP: The number of microRNAs are in positive set and their scores are
below the threshold.
• FP: The number of microRNAs are in negative set or they are not in
positive set and their scores are below the threshold.
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Figure 3: The AUC for all of the p-value combining tests.
• TN: The number of microRNAs are in negative set or they are not in
positive and their scores are above the threshold.
• FN: The number of microRNAs are in positive set and their scores are
above the threshold.
To select the best test for combining the p-value, we combined the three
lists of p-values by all tests and then we calculated AUC for each tests results
are shown in Figure 3. As shown in Figure 3, the best result is for sumlog
test by 82%, so we choose this test for combining the three lists of p-values.
For more comparing the tests to combine the p-value we combined the
three lists of p-values and we calculated AUC for 65, 130, and 260 number of
9
logtip meanp sumlog sump sumz wilkinsonp
0
0.2
0.4
0.6
0.8
1
AU
C 
Va
lu
e
|miRNA|=65
|miRNA|=130
|miRNA|=260
|miRNA|=312 (total)
Figure 4: Bar chart for comparing the tests to combine the p-value.
the microRNAs from the top of the ranked list of microRNAs and the result
of the comparison of tests are shown by bar chart in Figure 4.
According the results that achieved from tests of p-value combining, sum-
log choose to combine p-value. So, we combined three ranked list of p-value
with sumlog and then arranged the list of combined p-vlaues in ascending
order. The lower the p-value for a microRNA, the greater the probability
that this microRNA is associated with the cancer.
In Table 1 the 10 top of the list of the ranked microRNAs with CAMI-
RADA and the role of microRNAs in breast cancer are shown.
4. Conclusion
The identification of novel cancer-associated microRNAs is important for
diagnosing cancer in primary steps for treatment the cancer. In this study,
we presented a new approach (CAMIRADA) to identify microRNAs related
to breast cancer. CAMIRADA find the relationship between microRNAs and
cancer and it ranked microRNAs base on their relation with cancer, by us-
ing the microRNAs-disease genes associated, the DEGs-microRNAs related,
and the TFs-microRNAs relation. To evaluated CAMIRADA algorithm we
calculated AUC which was 0.95 for 65 microRNAs in top of the ranked list of
microRNAs. CAMIRADA showed that TFs and DEGs have important roles
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Table 1: The 10 top of the list of the ranked microRNAs.
microRNAs p-value role of microRNAs in breast cancer
hsa-miR-93 [26] 0.000679 Tumor suppressor
hsa-miR-526b [27] 0.000702 Oncogene
hsa-miR-17 [28] 0.000951 Oncogene
hsa-miR-20b [29] 0.00125 Oncogene
hsa-miR-199a [30] 0.001486 Tumor suppressor
hsa-miR-20a [31] 0.001529 Oncogene
hsa-miR-149 [32] 0.0020011 Oncogene
hsa-miR-199b [33] 0.00265 Biomarker
hsa-miR-519d [38] 0.002863 Oncogene
hsa-miR-502 [34] 0.036284 Tumor suppressor
for identification of which microRNA is related to cancer, so for showing the
influence of them we combined three ranked lists of p-values by sumlog test.
By using CAMIRADA, we predicted eight novel microRNAs including
hsa-miR-93, hsa-miR-526b, hsa-miR-20b, hsa-miR-199a, hsa-miR-6884, hsa-
miR-199b, and hsa-miR-519d associated to breast cancer which are not yet
recorded in the disease-microRNA association HMDD and miR2Disease. For
future studies, our methods can be used to identify which microRNAs are
related which cancers, we can make a network for each microRNA and asso-
ciated cancers, then analysis the network and extract information to identify
related between cancers.
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